Viridian Therapeutics Inc
VRDN29.250USD
+0.080+0.27%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.41BMarket Cap
LossP/E TTM
More Details of Viridian Therapeutics Inc Company
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian Therapeutics Inc Info
Ticker SymbolVRDN
Company nameViridian Therapeutics Inc
IPO dateJun 18, 2014
CEOMahoney (Stephen)
Number of employees143
Security typeOrdinary Share
Fiscal year-endJun 18
Address221 Crescent Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02453
Phone16172724600
Websitehttps://www.viridiantherapeutics.com/
Ticker SymbolVRDN
IPO dateJun 18, 2014
CEOMahoney (Stephen)
Company Executives of Viridian Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas W. Beetham
Mr. Thomas W. Beetham
Chief Operating Officer
Chief Operating Officer
7.00K
+2000.00%
Mr. Seth Harmon
Mr. Seth Harmon
Chief Financial Officer
Chief Financial Officer
2.61K
+1614.00%
Ms. Jennifer Tousignant
Ms. Jennifer Tousignant
Chief Legal Officer
Chief Legal Officer
1.54K
+1537.00%
Ms. Arlene M. Morris
Ms. Arlene M. Morris
Independent Director
Independent Director
--
--
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jennifer K. Moses
Ms. Jennifer K. Moses
Independent Director
Independent Director
--
--
Dr. Sarah Gheuens, M.D., Ph.D.
Dr. Sarah Gheuens, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Stephen (Steve) Mahoney
Mr. Stephen (Steve) Mahoney
President, Chief Executive Officer, Director (Principal Executive Officer)
President, Chief Executive Officer, Director (Principal Executive Officer)
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Christopher Cain
Dr. Christopher Cain
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas W. Beetham
Mr. Thomas W. Beetham
Chief Operating Officer
Chief Operating Officer
7.00K
+2000.00%
Mr. Seth Harmon
Mr. Seth Harmon
Chief Financial Officer
Chief Financial Officer
2.61K
+1614.00%
Ms. Jennifer Tousignant
Ms. Jennifer Tousignant
Chief Legal Officer
Chief Legal Officer
1.54K
+1537.00%
Ms. Arlene M. Morris
Ms. Arlene M. Morris
Independent Director
Independent Director
--
--
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jennifer K. Moses
Ms. Jennifer K. Moses
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
70.57M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.42%
The Vanguard Group, Inc.
5.86%
Deep Track Capital LP
5.64%
BlackRock Institutional Trust Company, N.A.
4.95%
Kynam Capital Management LP
4.64%
Other
67.49%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.42%
The Vanguard Group, Inc.
5.86%
Deep Track Capital LP
5.64%
BlackRock Institutional Trust Company, N.A.
4.95%
Kynam Capital Management LP
4.64%
Other
67.49%
Shareholder Types
Shareholders
Proportion
Hedge Fund
35.72%
Investment Advisor
35.46%
Investment Advisor/Hedge Fund
20.62%
Venture Capital
8.47%
Private Equity
1.53%
Research Firm
1.53%
Sovereign Wealth Fund
1.27%
Pension Fund
0.66%
Bank and Trust
0.36%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
385
99.38M
104.13%
-8.40M
2025Q3
368
96.50M
101.72%
-9.82M
2025Q2
368
94.63M
115.87%
-12.44M
2025Q1
387
93.96M
114.21%
-15.28M
2024Q4
381
93.18M
114.36%
-9.55M
2024Q3
354
88.84M
112.43%
+6.26M
2024Q2
331
71.47M
112.09%
-12.60M
2024Q1
329
71.87M
114.62%
-2.66M
2023Q4
309
61.41M
117.06%
+4.73M
2023Q3
286
52.92M
124.61%
-2.63M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
10.90M
11.42%
+197.95K
+1.85%
Sep 30, 2025
The Vanguard Group, Inc.
4.32M
4.52%
-176.53K
-3.93%
Sep 30, 2025
Deep Track Capital LP
5.38M
5.64%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.73M
4.95%
-43.72K
-0.92%
Sep 30, 2025
Kynam Capital Management LP
4.43M
4.64%
--
--
Sep 30, 2025
Fairmount Funds Management LLC
3.91M
4.1%
+454.55K
+13.14%
Oct 23, 2025
VR Adviser, LLC
3.88M
4.07%
--
--
Sep 30, 2025
Commodore Capital LP
3.20M
3.35%
-1.68M
-34.36%
Sep 30, 2025
Tang Capital Management, LLC
2.84M
2.98%
--
--
Sep 30, 2025
Paradigm BioCapital Advisors LP
2.61M
2.73%
-132.22K
-4.82%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
3.62%
Virtus LifeSci Biotech Clinical Trials ETF
1.02%
ALPS Medical Breakthroughs ETF
0.82%
State Street SPDR S&P Biotech ETF
0.6%
JPMorgan Healthcare Leaders ETF
0.49%
First Trust Small Cap Growth AlphaDEX Fund
0.43%
iShares Micro-Cap ETF
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.24%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.1%
ProShares Hedge Replication ETF
0.09%
View more
Simplify Propel Opportunities ETF
Proportion3.62%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.02%
ALPS Medical Breakthroughs ETF
Proportion0.82%
State Street SPDR S&P Biotech ETF
Proportion0.6%
JPMorgan Healthcare Leaders ETF
Proportion0.49%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.43%
iShares Micro-Cap ETF
Proportion0.32%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.24%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.1%
ProShares Hedge Replication ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
